---
title: "Cost-effectiveness of alternative approaches to hepatitis C diagnosis and treatment initiation for treatment-naive people who inject drugs in Australia"
author: "Chris Bailie"
date: "2024-06-04"
output: html_document
---







# Base-case

**Table 3.** Estimated cost-effectiveness of hepatitis C treatment initiation strategies in achieving treatment initiation/completion for treatment-naive people who inject drugs under base-case assumptions (costs in 2023 AUD). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

```
## Joining with `by = join_by(endpoint, strat)`
## `summarise()` has grouped output by 'endpoint'. You can override using the
## `.groups` argument.
## Joining with `by = join_by(endpoint, strat)`
```

<table class="table" style="margin-left: auto; margin-right: auto;">
 <thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1"></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="3"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Average</div></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="3"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Incremental to standard of care</div></th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1"></th>
</tr>
  <tr>
   <th style="text-align:left;"> Strategy </th>
   <th style="text-align:left;"> Cost </th>
   <th style="text-align:left;"> Effectiveness </th>
   <th style="text-align:left;"> Cost-effectiveness ratio </th>
   <th style="text-align:left;"> Cost </th>
   <th style="text-align:left;"> Effectiveness </th>
   <th style="text-align:left;"> Cost-effectiveness ratio </th>
   <th style="text-align:left;"> Willingness to pay thresholds for which strategy maximises net monetary benefit </th>
  </tr>
 </thead>
<tbody>
  <tr grouplength="7"><td colspan="8" style="border-bottom: 1px solid;"><strong>Treatment completion</strong></td></tr>
<tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (re-collection) </td>
   <td style="text-align:left;"> $1,154 </td>
   <td style="text-align:left;"> 0.023 </td>
   <td style="text-align:left;"> $49,555 </td>
   <td style="text-align:left;"> $0 </td>
   <td style="text-align:left;"> 0.0000 </td>
   <td style="text-align:left;"> - </td>
   <td style="text-align:left;"> $0 - $48,200 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (reflex) </td>
   <td style="text-align:left;"> $1,636 </td>
   <td style="text-align:left;"> 0.033 </td>
   <td style="text-align:left;"> $49,174 </td>
   <td style="text-align:left;"> $482 </td>
   <td style="text-align:left;"> 0.0100 </td>
   <td style="text-align:left;"> $48,285 </td>
   <td style="text-align:left;"> $48,300 - $57,300 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / PoC RNA </td>
   <td style="text-align:left;"> $2,026 </td>
   <td style="text-align:left;"> 0.040 </td>
   <td style="text-align:left;"> $50,555 </td>
   <td style="text-align:left;"> $872 </td>
   <td style="text-align:left;"> 0.0168 </td>
   <td style="text-align:left;"> $51,943 </td>
   <td style="text-align:left;"> $57,400 - $102,400 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC RNA </td>
   <td style="text-align:left;"> $2,357 </td>
   <td style="text-align:left;"> 0.043 </td>
   <td style="text-align:left;"> $54,427 </td>
   <td style="text-align:left;"> $1,203 </td>
   <td style="text-align:left;"> 0.0200 </td>
   <td style="text-align:left;"> $60,098 </td>
   <td style="text-align:left;"> $102,500 - $151,800 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA / early Tx </td>
   <td style="text-align:left;"> $3,002 </td>
   <td style="text-align:left;"> 0.048 </td>
   <td style="text-align:left;"> $63,130 </td>
   <td style="text-align:left;"> $1,848 </td>
   <td style="text-align:left;"> 0.0243 </td>
   <td style="text-align:left;"> $76,165 </td>
   <td style="text-align:left;"> $\geq$ $151,900 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA </td>
   <td style="text-align:left;"> $1,490 </td>
   <td style="text-align:left;"> 0.030 </td>
   <td style="text-align:left;"> $49,992 </td>
   <td style="text-align:left;"> $335 </td>
   <td style="text-align:left;"> 0.0065 </td>
   <td style="text-align:left;"> $51,557 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab RNA </td>
   <td style="text-align:left;"> $1,683 </td>
   <td style="text-align:left;"> 0.033 </td>
   <td style="text-align:left;"> $50,581 </td>
   <td style="text-align:left;"> $529 </td>
   <td style="text-align:left;"> 0.0100 </td>
   <td style="text-align:left;"> $52,976 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr grouplength="7"><td colspan="8" style="border-bottom: 1px solid;"><strong>Treatment initiation</strong></td></tr>
<tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (re-collection) </td>
   <td style="text-align:left;"> $53 </td>
   <td style="text-align:left;"> 0.039 </td>
   <td style="text-align:left;"> $1,352 </td>
   <td style="text-align:left;"> $0 </td>
   <td style="text-align:left;"> 0.0000 </td>
   <td style="text-align:left;"> - </td>
   <td style="text-align:left;"> $0 - $600 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (reflex) </td>
   <td style="text-align:left;"> $64 </td>
   <td style="text-align:left;"> 0.056 </td>
   <td style="text-align:left;"> $1,127 </td>
   <td style="text-align:left;"> $10 </td>
   <td style="text-align:left;"> 0.0169 </td>
   <td style="text-align:left;"> $602 </td>
   <td style="text-align:left;"> $700 - $1,100 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA / early Tx </td>
   <td style="text-align:left;"> $122 </td>
   <td style="text-align:left;"> 0.107 </td>
   <td style="text-align:left;"> $1,139 </td>
   <td style="text-align:left;"> $69 </td>
   <td style="text-align:left;"> 0.0680 </td>
   <td style="text-align:left;"> $1,015 </td>
   <td style="text-align:left;"> $\geq$ $1,200 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / PoC RNA </td>
   <td style="text-align:left;"> $101 </td>
   <td style="text-align:left;"> 0.068 </td>
   <td style="text-align:left;"> $1,483 </td>
   <td style="text-align:left;"> $47 </td>
   <td style="text-align:left;"> 0.0284 </td>
   <td style="text-align:left;"> $1,666 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA </td>
   <td style="text-align:left;"> $81 </td>
   <td style="text-align:left;"> 0.051 </td>
   <td style="text-align:left;"> $1,609 </td>
   <td style="text-align:left;"> $28 </td>
   <td style="text-align:left;"> 0.0110 </td>
   <td style="text-align:left;"> $2,532 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab RNA </td>
   <td style="text-align:left;"> $110 </td>
   <td style="text-align:left;"> 0.056 </td>
   <td style="text-align:left;"> $1,957 </td>
   <td style="text-align:left;"> $57 </td>
   <td style="text-align:left;"> 0.0169 </td>
   <td style="text-align:left;"> $3,370 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC RNA </td>
   <td style="text-align:left;"> $165 </td>
   <td style="text-align:left;"> 0.073 </td>
   <td style="text-align:left;"> $2,246 </td>
   <td style="text-align:left;"> $112 </td>
   <td style="text-align:left;"> 0.0339 </td>
   <td style="text-align:left;"> $3,287 </td>
   <td style="text-align:left;"> - </td>
  </tr>
</tbody>
</table>

<img src="HCV_treatment_initiation20240604_files/figure-html/base_analysis_nmb_completion-1.png" width="672" />

**Figure 2.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment completion for treatment-naive people who inject drugs, under base-case assumptions. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/base_analysis_nmb_initiation-1.png" width="672" />

**Figure 3.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs, under base-case assumptions.

# Univariate deterministic sensitivity analysis

```
## Warning: There was 1 warning in `mutate()`.
## ℹ In argument: `across(!y, ~NA)`.
## Caused by warning:
## ! Using an external vector in selections was deprecated in tidyselect 1.1.0.
## ℹ Please use `all_of()` or `any_of()` instead.
##   # Was:
##   data %>% select(y)
## 
##   # Now:
##   data %>% select(all_of(y))
## 
## See <https://tidyselect.r-lib.org/reference/faq-external-vector.html>.
```

<img src="HCV_treatment_initiation20240604_files/figure-html/univariate_dsa-1.png" width="2400" />

**Supplementary figure 2.** Results of deterministic sensitivity analysis for estimated cost-effectiveness of hepatitis C treatment initiation strategies (2023 AUD) in achieving treatment initiation/completion for treatment-naive people who inject drugs. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Probabilistic analysis

**Supplementary table 1.** Estimated cost-effectiveness of hepatitis C treatment initiation strategies in achieving treatment initiation/completion for treatment-naive people who inject drugs, under probabilistic assumptions (costs in 2023 AUD). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

```
## Joining with `by = join_by(iter, endpoint, strat)`
## `summarise()` has grouped output by 'endpoint'. You can override using the
## `.groups` argument.
## `summarise()` has grouped output by 'endpoint'. You can override using the
## `.groups` argument.
## Joining with `by = join_by(endpoint, strat)`
```

<table class="table" style="margin-left: auto; margin-right: auto;">
 <thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1"></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="3"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Average</div></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="3"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Incremental to standard of care</div></th>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1"></th>
</tr>
  <tr>
   <th style="text-align:left;"> Strategy </th>
   <th style="text-align:left;"> Cost </th>
   <th style="text-align:left;"> Effectiveness </th>
   <th style="text-align:left;"> Cost-effectiveness ratio </th>
   <th style="text-align:left;"> Cost </th>
   <th style="text-align:left;"> Effectiveness </th>
   <th style="text-align:left;"> Cost-effectiveness ratio </th>
   <th style="text-align:left;"> Willingness to pay thresholds for which strategy minimises expected net loss </th>
  </tr>
 </thead>
<tbody>
  <tr grouplength="7"><td colspan="8" style="border-bottom: 1px solid;"><strong>Treatment completion</strong></td></tr>
<tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (re-collection) </td>
   <td style="text-align:left;"> $1,174 </td>
   <td style="text-align:left;"> 0.024 </td>
   <td style="text-align:left;"> $49,822 </td>
   <td style="text-align:left;"> $0.0 </td>
   <td style="text-align:left;"> 0.0000 </td>
   <td style="text-align:left;"> - </td>
   <td style="text-align:left;"> $0 - $48,400 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (reflex) </td>
   <td style="text-align:left;"> $1,663 </td>
   <td style="text-align:left;"> 0.034 </td>
   <td style="text-align:left;"> $49,399 </td>
   <td style="text-align:left;"> $489.3 </td>
   <td style="text-align:left;"> 0.0101 </td>
   <td style="text-align:left;"> $48,413 </td>
   <td style="text-align:left;"> $48,500 - $61,000 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / PoC RNA </td>
   <td style="text-align:left;"> $2,046 </td>
   <td style="text-align:left;"> 0.040 </td>
   <td style="text-align:left;"> $51,232 </td>
   <td style="text-align:left;"> $871.9 </td>
   <td style="text-align:left;"> 0.0164 </td>
   <td style="text-align:left;"> $53,263 </td>
   <td style="text-align:left;"> $61,100 - $120,300 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC RNA </td>
   <td style="text-align:left;"> $2,451 </td>
   <td style="text-align:left;"> 0.043 </td>
   <td style="text-align:left;"> $56,608 </td>
   <td style="text-align:left;"> $1,277.3 </td>
   <td style="text-align:left;"> 0.0197 </td>
   <td style="text-align:left;"> $64,710 </td>
   <td style="text-align:left;"> $120,400 - $188,500 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA / early Tx </td>
   <td style="text-align:left;"> $2,931 </td>
   <td style="text-align:left;"> 0.046 </td>
   <td style="text-align:left;"> $63,922 </td>
   <td style="text-align:left;"> $1,756.6 </td>
   <td style="text-align:left;"> 0.0223 </td>
   <td style="text-align:left;"> $78,836 </td>
   <td style="text-align:left;"> $\geq$ $188,600 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA </td>
   <td style="text-align:left;"> $1,494 </td>
   <td style="text-align:left;"> 0.030 </td>
   <td style="text-align:left;"> $50,174 </td>
   <td style="text-align:left;"> $319.5 </td>
   <td style="text-align:left;"> 0.0062 </td>
   <td style="text-align:left;"> $51,510 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab RNA </td>
   <td style="text-align:left;"> $1,710 </td>
   <td style="text-align:left;"> 0.034 </td>
   <td style="text-align:left;"> $50,778 </td>
   <td style="text-align:left;"> $535.7 </td>
   <td style="text-align:left;"> 0.0101 </td>
   <td style="text-align:left;"> $53,009 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr grouplength="7"><td colspan="8" style="border-bottom: 1px solid;"><strong>Treatment initiation</strong></td></tr>
<tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (re-collection) </td>
   <td style="text-align:left;"> $56 </td>
   <td style="text-align:left;"> 0.040 </td>
   <td style="text-align:left;"> $1,404 </td>
   <td style="text-align:left;"> $0.0 </td>
   <td style="text-align:left;"> 0.0000 </td>
   <td style="text-align:left;"> - </td>
   <td style="text-align:left;"> $0 - $500 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab Ab / Lab RNA (reflex) </td>
   <td style="text-align:left;"> $66 </td>
   <td style="text-align:left;"> 0.057 </td>
   <td style="text-align:left;"> $1,156 </td>
   <td style="text-align:left;"> $9.9 </td>
   <td style="text-align:left;"> 0.0172 </td>
   <td style="text-align:left;"> $577 </td>
   <td style="text-align:left;"> $600 - $1,100 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA / early Tx </td>
   <td style="text-align:left;"> $123 </td>
   <td style="text-align:left;"> 0.107 </td>
   <td style="text-align:left;"> $1,141 </td>
   <td style="text-align:left;"> $66.3 </td>
   <td style="text-align:left;"> 0.0674 </td>
   <td style="text-align:left;"> $984 </td>
   <td style="text-align:left;"> $\geq$ $1,200 </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / PoC RNA </td>
   <td style="text-align:left;"> $101 </td>
   <td style="text-align:left;"> 0.068 </td>
   <td style="text-align:left;"> $1,494 </td>
   <td style="text-align:left;"> $45.2 </td>
   <td style="text-align:left;"> 0.0278 </td>
   <td style="text-align:left;"> $1,624 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC Ab / Lab RNA </td>
   <td style="text-align:left;"> $82 </td>
   <td style="text-align:left;"> 0.051 </td>
   <td style="text-align:left;"> $1,615 </td>
   <td style="text-align:left;"> $25.5 </td>
   <td style="text-align:left;"> 0.0105 </td>
   <td style="text-align:left;"> $2,416 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> Lab RNA </td>
   <td style="text-align:left;"> $113 </td>
   <td style="text-align:left;"> 0.057 </td>
   <td style="text-align:left;"> $1,967 </td>
   <td style="text-align:left;"> $56.4 </td>
   <td style="text-align:left;"> 0.0172 </td>
   <td style="text-align:left;"> $3,281 </td>
   <td style="text-align:left;"> - </td>
  </tr>
  <tr>
   <td style="text-align:left;padding-left: 2em;" indentlevel="1"> PoC RNA </td>
   <td style="text-align:left;"> $167 </td>
   <td style="text-align:left;"> 0.074 </td>
   <td style="text-align:left;"> $2,262 </td>
   <td style="text-align:left;"> $110.3 </td>
   <td style="text-align:left;"> 0.0336 </td>
   <td style="text-align:left;"> $3,286 </td>
   <td style="text-align:left;"> - </td>
  </tr>
</tbody>
</table>

<img src="HCV_treatment_initiation20240604_files/figure-html/psa_enl_completion-1.png" width="672" />

**Supplementary figure 3.** Expected net loss (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment completion for treatment-naive people who inject drugs, under probabilistic assumptions. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/psa_enl_initiation-1.png" width="672" />

**Supplementary figure 4.** Expected net loss (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs, under probabilistic assumptions. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Scenario 1.1: varying HCV prevalence (medium-high)

```
## Joining with `by = join_by(rna_prev.h, ab_pos_in_rna_neg.h, endpoint, strat)`
## `summarise()` has grouped output by 'endpoint', 'rna_prev.h',
## 'ab_pos_in_rna_neg.h'. You can override using the `.groups` argument.
## Joining with `by = join_by(endpoint, rna_prev.h, ab_pos_in_rna_neg.h, strat)`
```

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.1_nmb_completion-1.png" width="960" />

**Supplementary figure 5.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment completion for treatment-naive people who inject drugs, under varying prevalence (medium/high prevalence settings). Only strategies on the net monetary benefit frontier are shown. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.1_nmb_initiation-1.png" width="960" />

**Supplementary figure 6.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs, under varying prevalence (medium/high prevalence settings). Only strategies on the net monetary benefit frontier are shown. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.1_av_ce_completion-1.png" width="960" />

**Supplementary figure 7.** Estimated cost-effectiveness (2023 AUD) of hepatitis C treatment initiation strategies in achieving treatment completion for treatment-naive people who inject drugs, under varying prevalence (medium/high prevalence settings). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.1_av_ce_initiation-1.png" width="960" />

**Supplementary figure 8.** Estimated cost-effectiveness (2023 AUD) of hepatitis C treatment initiation strategies in achieving treatment initiation for treatment-naive people who inject drugs, under varying prevalence (medium/high prevalence settings). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Scenario 1.2: varying HCV prevalence (low)

```
## Joining with `by = join_by(rna_prev.l, ab_pos_in_rna_neg.l, endpoint, strat)`
## `summarise()` has grouped output by 'endpoint', 'rna_prev.l',
## 'ab_pos_in_rna_neg.l'. You can override using the `.groups` argument.
## Joining with `by = join_by(endpoint, rna_prev.l, ab_pos_in_rna_neg.l, strat)`
```

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.2_nmb_completion-1.png" width="960" />

**Supplementary figure 9.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs, under varying prevalence (low prevalence settings). Only strategies on the net monetary benefit frontier are shown. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.2_nmb_initiation-1.png" width="960" />

**Supplementary figure 10.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs, under varying prevalence (low prevalence settings). Only strategies on the net monetary benefit frontier are shown. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.2_av_ce_completion-1.png" width="960" />

**Supplementary figure 11.** Estimated cost-effectiveness (2023 AUD) of hepatitis C treatment initiation strategies in achieving treatment completion for treatment-naive people who inject drugs, under varying prevalence (low prevalence settings). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_1.2_av_ce_initiation-1.png" width="960" />

**Supplementary figure 12.** Estimated cost-effectiveness (2023 AUD) of hepatitis C treatment initiation strategies in achieving treatment initiation for treatment-naive people who inject drugs, under varying prevalence (low prevalence settings). Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Scenario 2: varying LTFU for s2.b

```
## Joining with `by = join_by(alt_p14, alt_p15, endpoint, strat)`
## `summarise()` has grouped output by 'endpoint', 'alt_p14', 'alt_p15'. You can
## override using the `.groups` argument.
## Joining with `by = join_by(endpoint, alt_p14, alt_p15, strat)`
```

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_2_nmb_completion-1.png" width="960" />

**Supplementary figure 13.** Estimated net monetary benefit (2023 AUD) of a *point-of-care antibody/laboratory RNA/early treatment* hepatitis C treatment initiation strategy under varying loss to follow up assumptions, and the net monetary benefit frontier presented by competing strategies, by willingness to pay per additional treatment completion for treatment-naive people who inject drugs. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_2_nmb_initiation-1.png" width="960" />

**Supplementary figure 14.** Estimated net monetary benefit (2023 AUD) of a *point-of-care antibody/laboratory RNA/early treatment* hepatitis C treatment initiation strategy under varying loss to follow up assumptions, and the net monetary benefit frontier presented by competing strategies, by willingness to pay per additional treatment initiation for treatment-naive people who inject drugs. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.


```
## `summarise()` has grouped output by 'endpoint'. You can override using the
## `.groups` argument.
## Joining with `by = join_by(endpoint, strat)`
```

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_2_av_ce-1.png" width="960" />

**Supplementary figure 15.** Estimated cost-effectiveness (2023 AUD) of a *point-of-care antibody/laboratory RNA/early treatment* hepatitis C treatment initiation strategy in achieving treatment completion/initiation for treatment-naive people who inject drugs under optimistic and pessimistic loss to follow up assumptions (error bars). Estimates for other strategies under base-case assumptions shown for comparison. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Scenario 3: varying medication costs

```
## Joining with `by = join_by(discount, endpoint, strat)`
## `summarise()` has grouped output by 'endpoint', 'discount'. You can override
## using the `.groups` argument.
## Joining with `by = join_by(endpoint, discount, strat)`
```

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_3_nmb_completion-1.png" width="960" />

**Supplementary figure 16.** Estimated net monetary benefit (2023 AUD) of hepatitis C treatment initiation strategies by willingness to pay per additional treatment completion for treatment-naive people who inject drugs, under varying medication costs. Only strategies on the net monetary benefit frontier are shown. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

<img src="HCV_treatment_initiation20240604_files/figure-html/scenario_3_av_ce_completion-1.png" width="960" />

**Supplementary figure 17.** Estimated cost-effectiveness (2023 AUD) of hepatitis C treatment initiation strategies in achieving treatment completion for treatment-naive people who inject drugs, under varying medication costs. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.

# Treatments by viraemic status

**Supplementary table 2.** Estimated treatment initiations/completions in viraemic and non-viraemic individuals resulting from hepatitis C treatment initiation strategies for treatment-naive people who inject drugs under the base-case assumptions. Abbreviations: Ab: antibody; Lab: laboratory; PoC: point-of-care; RNA: ribonucleic acid; Tx: treatment.
<table class="table" style="margin-left: auto; margin-right: auto;">
 <thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1"></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Completions per 1000 screened</div></th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2"><div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">Initiations per 1000 screened</div></th>
</tr>
  <tr>
   <th style="text-align:left;"> Strategy </th>
   <th style="text-align:left;"> Viraemic </th>
   <th style="text-align:left;"> Non-viraemic </th>
   <th style="text-align:left;"> Viraemic </th>
   <th style="text-align:left;"> Non-viraemic </th>
  </tr>
 </thead>
<tbody>
  <tr>
   <td style="text-align:left;"> Lab Ab / Lab RNA (re-collection) </td>
   <td style="text-align:left;"> 23 </td>
   <td style="text-align:left;"> 0.00 </td>
   <td style="text-align:left;"> 39 </td>
   <td style="text-align:left;"> 0.0 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> Lab Ab / Lab RNA (reflex) </td>
   <td style="text-align:left;"> 33 </td>
   <td style="text-align:left;"> 0.00 </td>
   <td style="text-align:left;"> 56 </td>
   <td style="text-align:left;"> 0.0 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> Lab RNA </td>
   <td style="text-align:left;"> 33 </td>
   <td style="text-align:left;"> 0.00 </td>
   <td style="text-align:left;"> 56 </td>
   <td style="text-align:left;"> 0.0 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> PoC Ab / Lab RNA </td>
   <td style="text-align:left;"> 30 </td>
   <td style="text-align:left;"> 0.00 </td>
   <td style="text-align:left;"> 51 </td>
   <td style="text-align:left;"> 0.0 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> PoC Ab / Lab RNA / early Tx </td>
   <td style="text-align:left;"> 48 </td>
   <td style="text-align:left;"> 0.00 </td>
   <td style="text-align:left;"> 107 </td>
   <td style="text-align:left;"> 182.5 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> PoC Ab / PoC RNA </td>
   <td style="text-align:left;"> 40 </td>
   <td style="text-align:left;"> 0.66 </td>
   <td style="text-align:left;"> 68 </td>
   <td style="text-align:left;"> 1.1 </td>
  </tr>
  <tr>
   <td style="text-align:left;"> PoC RNA </td>
   <td style="text-align:left;"> 43 </td>
   <td style="text-align:left;"> 3.07 </td>
   <td style="text-align:left;"> 73 </td>
   <td style="text-align:left;"> 5.2 </td>
  </tr>
</tbody>
</table>
